미국의 자동 및 폐쇄형 세포치료 처리 시스템 시장 : 시장 규모, 점유율, 동향 분석 보고서-워크플로우별, 유형별, 스케일별, 부문별 예측(2025-2030년)

U.S. Automated And Closed Cell Therapy Processing Systems Market Growth & Trends:

The U.S. automated and closed cell therapy processing systems market size is anticipated to reach USD 1.87 billion by 2030, growing at a CAGR of 19.41% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing emphasis on regenerative medicines and cell therapies, operational superiority of automated systems over manual processing, and extensively increasing technological advancements are some of the major factors driving the growth of the market.

The growing awareness about regenerative medicine is expected to drive the demand for cell therapies, eventually driving the need for automated and closed-cell therapy processing systems and fueling market growth. For instance, in September 2024, Arsenal Biosciences completed a USD 325 million Series C funding round, which was oversubscribed. This funding will help the company advance its CAR T-cell therapies for solid tumors. Existing investors supported the company, including the Parker Institute for Cancer Immunotherapy, SoftBank Vision Fund 2, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.

The COVID-19 pandemic underscored the critical need for scalable, resilient manufacturing in cell therapies, emphasizing automated systems' role in ensuring consistent, repeatable quality processes amid rising demand for therapeutics. Automation helps companies maintain production standards when faced with workforce constraints, making it essential for current and anticipated therapeutic needs. The increased adoption of automated systems highlighted the technology's role in establishing reliable, high-quality cell therapy manufacturing.

Despite these advancements, the pandemic also negatively affected the U.S. automated and closed-cell therapy processing systems market. Global supply chain disruptions caused delays in production and distribution, limiting the ability to maintain steady supply lines for essential equipment and materials. Resources were also redirected toward COVID-19 treatments, pausing certain cell therapy projects and slowing innovation. As a result, some development and manufacturing timelines for cell therapies were extended, impacting both research and commercialization efforts in the short term.

Moreover, many ongoing clinical trials coupled with the increasing support from government bodies to accelerate the R&D of cell therapy are major drivers of the U.S. market. For instance, in October 2024, New York launched the ambitious BioGenesis Park project on Long Island, supported by a USD 430 million investment. This facility aims to be a major hub for cell and gene therapy innovation, driven by a USD 150 million state investment and partnerships with local organizations. Such initiatives are expected to boost the adoption of automated systems for cell therapy manufacturing.

However, as the technology is relatively new, it requires a deep understanding of the process and a well-articulated strategy to achieve desired outcomes. Furthermore, providing enough data for the system to understand the process is necessary. After this step, one needs to understand process control for automation. This overall progression requires skilled manpower and high-end devices. There is a shortage of compatible hardware platforms that can help achieve automation in cell therapy processes. The need for extensive capital is expected to impede market growth to a certain extent.

U.S. Automated And Closed Cell Therapy Processing Systems Market Report Highlights:

• Based on workflow, the separation segment dominated the market with the highest revenue share of 31.10% in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. The large share is attributed to the increasing demand for efficient cell isolation and purification techniques in therapeutic applications
• Based on the type, the non-stem cell therapy segment dominated the market in 2024 with a share of 61.84%. This can be attributed to increasing product launches for non-stem cell therapy applications
• Based on scale, the pre-commercial/R&D scale segment held the largest share of 74.96% in 2024. These systems are used primarily in early-stage research, process development, and clinical trials

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Workflow Segment
  • 1.2.2. Type Segment
  • 1.2.3. Scale Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing emphasis on regenerative medicines and cell therapies
    • 3.2.1.2. Operational superiority of automated systems over manual processing
    • 3.2.1.3. Extensively increasing technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Complications associated with cell processing systems
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Automated and Closed Cell Therapy Processing Systems Market: Workflow Business Analysis

• 4.1. Workflow Segment Dashboard
• 4.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Workflow Movement Analysis
• 4.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 4.4. Separation
  • 4.4.1. Separation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Expansion
  • 4.5.1. Expansion Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Apheresis
  • 4.6.1. Apheresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Fill-finish
  • 4.7.1. Fill-finish Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Cryopreservation
  • 4.8.1. Cryopreservation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Automated and Closed Cell Therapy Processing Systems Market: Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Type, Movement Analysis
• 5.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis by Type, 2018 to 2030 (USD Million)
• 5.4. Stem Cell Therapy
  • 5.4.1. Stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Non-stem Cell Therapy
  • 5.5.1. Non-stem Cell Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Automated and Closed Cell Therapy Processing Systems Market: Scale Business Analysis

• 6.1. Scale Segment Dashboard
• 6.2. U.S. Automated and Closed Cell Therapy Processing Systems Market Scale Movement Analysis
• 6.3. U.S. Automated and Closed Cell Therapy Processing Systems Market Size & Trend Analysis, by Scale, 2018 to 2030 (USD Million)
• 6.4. Pre-commercial/ R&D Scale
  • 6.4.1. Pre-commercial/ R&D Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Commercial Scale
  • 6.5.1. Commercial Scale Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2024
• 7.4. Participant's Overview
  • 7.4.1. Thermo Fisher Scientific Inc.
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Lonza
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. MiltenyiBiotec
    • 7.4.3.1. Overview
    • 7.4.3.2. Product Benchmarking
    • 7.4.3.3. Strategic Initiatives
  • 7.4.4. Danaher
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Sartorius AG
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Fresenus
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. MaxCyte, Inc.
    • 7.4.7.1. Overview
    • 7.4.7.2. Product Benchmarking
    • 7.4.7.3. Strategic Initiatives
  • 7.4.8. ThermoGenesis Holdings, Inc.
    • 7.4.8.1. Overview
    • 7.4.8.2. Product Benchmarking
    • 7.4.8.3. Strategic Initiatives
  • 7.4.9. Terumo Corporation
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Cellares Inc.
    • 7.4.10.1. Overview
    • 7.4.10.2. Product Benchmarking
    • 7.4.10.3. Strategic Initiatives